Eli Lilly Chair & CEO Dave Ricks sits down with CNBC’s Annika Constantino to discuss the fourth location Lilly has committed ...

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? Novo Nordisk's weight ...

Eli Lilly (NYSE: LLY) has been experiencing fantastic growth due to the success of its GLP-1 drugs, Mounjaro (approved for ...

Medicare's upcoming coverage of obesity treatments could dramatically expand access to Eli Lilly's (NYSE:LLY) experimental weight-loss pill, orforglipron, CEO Dave Ricks said Friday. Medicare Coverage ...

According to the Centers for Disease Control and Prevention, 41.9 percent of U.S. adults were obese from 2017 to 2020.

Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.

Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...

The company said the new plant will make injectable drugs and devices, including producing weight-loss drug retatrutide, ...

We’ve all heard of Ozempic by now. It’s only licensed for use as a diabetes treatment in the UK and US, but it's widely used ...

The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.

Novo Nordisk (NVO) stock is set to outperform Eli Lilly (LLY) stock thanks mainly to a strong commercial rollout for the company's Wegovy pill. Read more here.

ALLENTOWN - In a big win for Pennsylvania and the Lehigh Valley, Eli Lilly & Co. has announced plans to build a $3.5 billion drug production plant in Lehigh County. Gov. Josh Shapiro says Lilly’s ...